The team will specialise in working with pharmaceutical, biotech, diagnostic and device companies, providing them with advanced analytics at early stage development for multiple therapy areas.

Prior to his time at Holden Pearmain, Margerison spent two years as a senior research executive at Research International (now Kantar Health) in London.

He was a director at Holden Pearmain for almost ten years until the agency called in administrators last month. At the time, Impact MD Darryl Swift – himself ex-Holden Pearmain – said he had offered jobs to three of the agency’s former staff.